Recent News

• 06.05.2026 - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.01.2026 - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.27.2026 - Intellia Announces Proposed Public Offering of Common Stock
• 04.24.2026 - Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
• 04.03.2026 - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 05.11.2026 - 8-K Current report
• 05.11.2026 - EX-99.1 EX-99.1
• 05.11.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.30.2026 - 8-K Current report
• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.30.2026 - ARS Annual Report to Security Holders
• 04.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.29.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.29.2026 - 424B5 Prospectus [Rule 424(b)(5)]